Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein
- PMID: 17381514
- DOI: 10.1111/j.1742-4658.2007.05733.x
Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein
Abstract
Accumulation of alpha-synuclein resulting in the formation of oligomers and protofibrils has been linked to Parkinson's disease and Lewy body dementia. In contrast, beta-synuclein (beta-syn), a close homologue, does not aggregate and reduces alpha-synuclein (alpha-syn)-related pathology. Although considerable information is available about the conformation of alpha-syn at the initial and end stages of fibrillation, less is known about the dynamic process of alpha-syn conversion to oligomers and how interactions with antiaggregation chaperones such as beta-synuclein might occur. Molecular modeling and molecular dynamics simulations based on the micelle-derived structure of alpha-syn showed that alpha-syn homodimers can adopt nonpropagating (head-to-tail) and propagating (head-to-head) conformations. Propagating alpha-syn dimers on the membrane incorporate additional alpha-syn molecules, leading to the formation of pentamers and hexamers forming a ring-like structure. In contrast, beta-syn dimers do not propagate and block the aggregation of alpha-syn into ring-like oligomers. Under in vitro cell-free conditions, alpha-syn aggregates formed ring-like structures that were disrupted by beta-syn. Similarly, cells expressing alpha-syn displayed increased ion current activity consistent with the formation of Zn(2+)-sensitive nonselective cation channels. These results support the contention that in Parkinson's disease and Lewy body dementia, alpha-syn oligomers on the membrane might form pore-like structures, and that the beneficial effects of beta-synuclein might be related to its ability to block the formation of pore-like structures.
Similar articles
-
Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.PLoS One. 2008 Sep 4;3(9):e3135. doi: 10.1371/journal.pone.0003135. PLoS One. 2008. Retraction in: PLoS One. 2025 Mar 18;20(3):e0321152. doi: 10.1371/journal.pone.0321152. PMID: 18769546 Free PMC article. Retracted.
-
Distinct higher-order α-synuclein oligomers induce intracellular aggregation.Biochem J. 2015 Jun 15;468(3):485-93. doi: 10.1042/BJ20150159. Epub 2015 Apr 8. Biochem J. 2015. PMID: 25851527
-
Comparative Analysis of the Conformation, Aggregation, Interaction, and Fibril Morphologies of Human α-, β-, and γ-Synuclein Proteins.Biochemistry. 2018 Jul 3;57(26):3830-3848. doi: 10.1021/acs.biochem.8b00343. Epub 2018 Jun 13. Biochemistry. 2018. PMID: 29851342
-
Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Mov Disord. 2013. PMID: 23390095 Review.
-
Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein.Neuropathol Appl Neurobiol. 2016 Feb;42(1):51-76. doi: 10.1111/nan.12299. Neuropathol Appl Neurobiol. 2016. PMID: 26666838 Review.
Cited by
-
Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein.PLoS One. 2023 Sep 21;18(9):e0291927. doi: 10.1371/journal.pone.0291927. eCollection 2023. PLoS One. 2023. PMID: 37733672 Free PMC article.
-
High-resolution structural information of membrane-bound α-synuclein provides insight into the MoA of the anti-Parkinson drug UCB0599.Proc Natl Acad Sci U S A. 2023 Apr 11;120(15):e2201910120. doi: 10.1073/pnas.2201910120. Epub 2023 Apr 7. Proc Natl Acad Sci U S A. 2023. PMID: 37027427 Free PMC article.
-
Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance.Neurotox Res. 2011 Nov;20(4):387-401. doi: 10.1007/s12640-011-9255-x. Epub 2011 Jul 7. Neurotox Res. 2011. PMID: 21735318 Free PMC article.
-
Differential protein structural disturbances and suppression of assembly partners produced by nonsense GABRG2 epilepsy mutations: implications for disease phenotypic heterogeneity.Sci Rep. 2016 Oct 20;6:35294. doi: 10.1038/srep35294. Sci Rep. 2016. PMID: 27762395 Free PMC article.
-
New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases.Neurogenetics. 2012 Feb;13(1):61-72. doi: 10.1007/s10048-011-0311-8. Epub 2011 Dec 29. Neurogenetics. 2012. PMID: 22205345
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous